A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

November 30, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Infections, Bacterial

Interventions

DRUG

GSK945237

Dose detailed in Arm description

DRUG

Placebo

matching placebo tablet

DRUG

Linezolid

600 mg BID, 14 Days

DRUG

Moxifloxacin

40 mg single dose